Companies: Vanda Pharmaceuticals, Vanda Pharmaceuticals Netherlands BV
Drugs: Tradipitant
Vanda tradipitant update: FDA re-review extends to Dec. 5, 2025
100% citation coverage2 regulatory sources1 peer-reviewed sources
Vanda Pharmaceuticals controversy now centers on tradipitant’s regulatory timeline and the next catalyst set. The FDA and Vanda agreed to extend the expedited re-review of the partial clinical hold to Dec. 5, 2025, while multiple tradipitant studies remain active or recruiting.
Intelligence Snapshot
Executive Summary
The FDA and Vanda agreed to extend the expedited re-review of the partial clinical hold on tradipitant to December 5, 2025, establishing a new regulatory timeline for the program.
Key Insights
-
NEREUS (tradipitant) is indicated for the prevention of vomiting induced by motion in…
NEREUS (tradipitant) is indicated for the prevention of vomiting induced by motion in adults , with the drug functioning as a substance P/neurokinin 1 (NK1) receptor antagonist.
-
Three active or recruiting clinical trials—two phase 3 studies and one phase 2…
Three active or recruiting clinical trials—two phase 3 studies and one phase 2 study—track tradipitant's potential across GLP-1 receptor agonist-induced nausea, motion sickness, and functional dyspepsia.
Market Impact
| Regulatory | high |
|---|---|
| Commercial | high |
| Competitive | medium |
| Investment | high |
Loading intelligence…
Quick Answer
Key Questions
- What changed with the FDA and Vanda's tradipitant agreement?
- Is tradipitant already FDA approved?
- What clinical trials are currently active for tradipitant?
- What is the next regulatory milestone for tradipitant?
- How does tradipitant work?
Executive Scorecard
Heuristic scores · directional, not investment adviceRegulatory catalyst tracker
Track PDUFA dates, approval milestones, and label updates for Tradipitant.
Unlock full calendar →Vanda Pharmaceuticals Netherlands B.V. pipeline snapshot
One-screen view of active programs, phases, and recent catalysts from public sources.
Investor brief
Download a one-page summary of regulatory impact and competitive context.
Explore drug hub →Contents13 sections
Vanda tradipitant update: FDA re-review extends to Dec. 5, 2025
Vanda Pharmaceuticals controversy now centers on tradipitant's regulatory timeline and the next catalyst set. The FDA and Vanda agreed to extend the expedited re-review of the partial clinical hold to Dec. 5, 2025, while multiple tradipitant studies remain active or recruiting.
IntelligenceRegulatory Impact
FDA decisions frame this story. Regulatory relevance is high for this topic, with Tradipitant most exposed. Track designations, submission types, and label or guidance shifts that could move timelines.
Key Takeaways
- The FDA and Vanda agreed to extend the expedited re-review of the partial clinical hold on tradipitant to December 5, 2025, establishing a new regulatory timeline for the program.
- NEREUS (tradipitant) is indicated for the prevention of vomiting induced by motion in adults, with the drug functioning as a substance P/neurokinin 1 (NK1) receptor antagonist.
- Three active or recruiting clinical trials—two phase 3 studies and one phase 2 study—track tradipitant's potential across GLP-1 receptor agonist-induced nausea, motion sickness, and functional dyspepsia.
IntelligenceCompetitive Intelligence
Vanda Pharmaceuticals and Vanda Pharmaceuticals Netherlands BV are directly implicated. Competitive pressure reads medium — compare pipeline positioning and partnership scouting against signals in this story.
What Changed: FDA Re-Review Extension for Tradipitant
The FDA and Vanda Pharmaceuticals agreed to an extension of the expedited re-review of the partial clinical hold on tradipitant through December 5, 2025. The extension establishes a defined regulatory timeline for both the agency and the company.
NEREUS (tradipitant) is indicated for the prevention of vomiting induced by motion in adults and is a substance P/neurokinin 1 (NK1) receptor antagonist. The approved indication establishes an existing commercial baseline while regulatory discussions continue on the program's next steps.
IntelligenceMarket Signals
Commercial pull is high and investment relevance high for this topic. Expect implications for pricing, access, and launch sequencing.
Clinical Pipeline: Active and Recruiting Trials
Vanda's clinical pipeline for tradipitant spans multiple therapeutic areas and trial phases. A phase 3 trial (NCT07446439) is currently recruiting to evaluate tradipitant on treating nausea and vomiting induced by GLP-1R agonist use. This study addresses nausea and vomiting in patients taking GLP-1 receptor agonists for obesity.
A second phase 3 trial (NCT06138613), Motion Delos, is active but not recruiting and evaluates the safety and efficacy of tradipitant in participants affected by motion sickness. This trial directly supports the approved NEREUS indication.
A phase 2 study (NCT05653310) is enrolling by invitation to evaluate tradipitant for functional dyspepsia. This trial represents early-stage exploration of the NK1 antagonist mechanism in a distinct patient population.
A phase 2 trial (NCT06804603) measuring the effects of tradipitant on nausea and vomiting after GLP-1R agonist use has been completed. The completion of this earlier-stage study provides a foundation for the phase 3 GLP-1R agonist program now recruiting.
IntelligenceStrategic Takeaways
The FDA and Vanda agreed to extend the expedited re-review of the partial clinical hold on tradipitant to December 5, 2025, establishing a new regulatory timeline for the program. NEREUS (tradipitant) is indicated for the prevention of vomiting induced by motion in adults , with the drug functioning as a substance P/neurokinin 1 (NK1) receptor antagonist. Three active or recruiting clinical trials—two phase 3 studies
Regulatory Milestones and Trial Timeline
The December 5, 2025 FDA re-review deadline is the most immediate regulatory milestone for the program. Investors tracking Vanda should monitor that date for any agency decision or further regulatory guidance affecting the program.
Parallel to the regulatory re-review, the recruiting phase 3 GLP-1R agonist trial (NCT07446439) and the active phase 3 motion sickness trial (NCT06138613) remain ongoing. The phase 2 functional dyspepsia study (NCT05653310) operates on a longer timeline and represents exploration of the NK1 antagonist platform in an additional therapeutic area.
IntelligenceEvidence Quality
Grounded in 2 regulatory sources and 1 peer-reviewed source.
Vanda Pharmaceuticals: Company Overview and Pipeline
Vanda Pharmaceuticals is a global biopharmaceutical company focused on the development and commercialization of therapies addressing high unmet medical needs. The company operates through subsidiaries including Vanda Pharmaceuticals Limited, Vanda Pharmaceuticals GmbH, and Vanda Pharmaceuticals Germany GmbH, establishing a footprint across key regulatory regions.
Tradipitant represents one element of Vanda's clinical pipeline. The approved NEREUS indication in motion sickness is established, while the phase 2 and phase 3 programs explore the drug's potential in GLP-1 related nausea and functional dyspepsia.
Drug Snapshot
| Drug | Tradipitant |
|---|---|
| Generic name | TRADIPITANT |
| Manufacturer | Vanda Pharmaceuticals Inc. |
| Route | ORAL |
| Indication | 1 INDICATIONS AND USAGE NEREUS is indicated for the prevention of vomiting induced by motion in adults. NEREUS is a substance P/neurokinin 1 (NK1) receptor antagonist indicated for the prevention of vomiting induced by motion in adults. ( 1 ) |
Regulatory Summary
- Approved indication: 1 INDICATIONS AND USAGE NEREUS is indicated for the prevention of vomiting induced by motion in adults. NEREUS is a substance P/neurokinin 1 (NK1) receptor antagonist indicated for the prevention of vomiting induced by motion in adults. ( 1 )
- Vanda Pharmaceuticals Inc. develops Tradipitant
Trial Snapshot
| Trial | Title | Status | Phase | Sponsor |
|---|---|---|---|---|
| NCT07446439 | A Study to Evaluate Tradipitant on Treating Nausea and Vomiting Induced by GLP-1R Agonist Use | RECRUITING | PHASE3 | Vanda Pharmaceuticals |
| NCT06138613 | Motion Delos: An Open Label Safety and Efficacy of Tradipitant in Participants Affected by Motion Sickness | ACTIVE_NOT_RECRUITING | PHASE3 | Vanda Pharmaceuticals |
| NCT05653310 | Tradipitant for Functional Dyspepsia | ENROLLING_BY_INVITATION | PHASE2 | Xiao Jing (Iris) Wang |
| NCT06804603 | A Study to Measure the Effects of Using Tradipitant on Nausea and Vomiting After GLP-1R Agonist Use | COMPLETED | PHASE2 | Vanda Pharmaceuticals |
| NCT04474990 | Single-Patient Expanded Access Protocol for Tradipitant In A Single Patient With Gastroparesis | AVAILABLE | — | Vanda Pharmaceuticals |
Timeline
- Recruiting trial NCT07446439 (PHASE3)
- Active_Not_Recruiting trial NCT06138613 (PHASE3)
- Enrolling_By_Invitation trial NCT05653310 (PHASE2)
Frequently Asked Questions
What changed with the FDA and Vanda's tradipitant agreement?
The FDA and Vanda agreed to extend the expedited re-review of the partial clinical hold on tradipitant to December 5, 2025. This extension provides a new regulatory milestone for the program.
Is tradipitant already FDA approved?
Yes. NEREUS (tradipitant) is indicated for the prevention of vomiting induced by motion in adults. The drug is a substance P/neurokinin 1 (NK1) receptor antagonist and is available as an oral formulation.
What clinical trials are currently active for tradipitant?
Three key trials are ongoing. A phase 3 trial (NCT07446439) is recruiting to evaluate tradipitant for nausea and vomiting induced by GLP-1R agonist use. A phase 3 trial (NCT06138613), Motion Delos, is active but not recruiting and evaluates tradipitant in participants with motion sickness. A phase 2 trial (NCT05653310) is enrolling by invitation to assess tradipitant for functional dyspepsia.
What is the next regulatory milestone for tradipitant?
December 5, 2025 is the deadline for the FDA's expedited re-review of the partial clinical hold. Investors and analysts should monitor that date for the agency's decision or any further regulatory guidance affecting the program's advancement.
How does tradipitant work?
NEREUS is a substance P/neurokinin 1 (NK1) receptor antagonist. Tradipitant is a novel neurokinin-1 receptor antagonist for motion sickness.
Is Vanda Pharmaceuticals an American company?
Vanda Pharmaceuticals is a global biopharmaceutical company. The company operates through subsidiaries including Vanda Pharmaceuticals Limited, Vanda Pharmaceuticals GmbH, and Vanda Pharmaceuticals Germany GmbH, establishing operations across key regulatory regions.
Related profiles
Related coverage
Continue Exploring
Jump into the entities behind this story.
Ask AI About This Topic
Grounded in NovaPharmaNews intelligence. Pick a prompt to start.
Follow Tradipitant developments
Get the latest drug approvals, clinical trials, and regulatory updates delivered to your inbox.
- Sources analyzed
- 3
- Evidence strength
- 89/100
- Last verified
- Jun 8, 2026
- AI-assisted review
- Yes
- Editorial review
- Dr. Sarah Chen
High source quality · grounded in cited primary and secondary sources.
This article follows our editorial standards. Report a correction via editorial contact.
